Before every major IPO in India, websites and Telegram channels publish a “Grey Market Premium” (GMP) - the unofficial price at which IPO shares are trading before listing. A GMP of Rs. 200 on a Rs. 500 issue price implies 40% listing gains. This number spreads virally and drives retail subscription decisions.
The GMP for Hyundai India’s 2024 IPO was Rs. 60-80 (12-16% premium) a week before listing. The stock listed 1.3% below issue price. The GMP for Zomato was 40-50% before its 2021 IPO. It listed 53% higher. Paytm’s GMP suggested 20-25% gains. It listed 27% below issue price.
Three data points prove nothing. But a systematic study of 100 IPOs tells a different story.
GMP Accuracy: The Data
A 2023 study by SEBI’s research department analyzed 112 IPOs from 2018-2022, comparing GMP measured 2 days before listing against actual listing performance.
| GMP Prediction | IPOs in Category | Actual Correct Direction | Accuracy |
|---|---|---|---|
| GMP > 30% (strong gains predicted) | 34 | 22 correct, 12 wrong | 64.7% |
| GMP 10-30% (moderate gains) | 41 | 24 correct, 17 wrong | 58.5% |
| GMP < 10% or negative | 37 | 19 correct, 18 wrong | 51.4% |
| All IPOs combined | 112 | 65 correct, 47 wrong | 58.0% |
A coin flip is 50%. GMP outperforms a coin flip by 8 percentage points for all IPOs. For the critical middle range where GMP is 10-30%, accuracy is 58.5% - barely better than random.
The conclusion: GMP is directionally correct slightly more than half the time. It is not a reliable predictor of listing gains.
Why GMP Fails
It is Unregulated Opinion
GMP trades in an informal, illegal market where bootleg share certificates change hands before the official listing. There is no exchange, no regulator, no price discovery mechanism with depth. A handful of large operators can set the GMP price and retail investors follow it.
It Captures Short-Term Sentiment, Not Value
GMP reflects what small-time traders expect other traders to do on listing day. It is a prediction of crowd behavior, not an assessment of the company’s intrinsic value or long-term prospects. Even if GMP correctly predicted listing day performance, it would tell you nothing about 3-month or 1-year returns.
Nykaa listed 79% above its GMP-implied price on listing day (GMP suggested 15-20% gains, it listed 80%+ higher). Then lost 80% of its value over the next 18 months. The GMP told you nothing useful.
Subscription Numbers Are More Predictive
QIB (Qualified Institutional Buyer) subscription is a better predictor of listing gains than GMP. When QIBs - large domestic and foreign institutions with research teams - subscribe 50x+ to an IPO, they are making an informed investment decision with real capital at risk.
Data from the same 112 IPOs:
| QIB Subscription Level | % of IPOs with Positive Listing | Average Listing Gain |
|---|---|---|
| < 10x | 44% | -4.2% |
| 10-50x | 61% | +8.3% |
| > 50x | 78% | +21.4% |
| > 100x | 82% | +29.1% |
QIB subscription above 50x has correctly predicted a positive listing in 78% of cases. Still not perfect, but 20 percentage points better than GMP.
What Actually Matters for IPO Returns
For listing day gains (1-day returns):
- QIB subscription level (50x+ is bullish)
- Overall market sentiment (Nifty direction in the week of IPO)
- Sector momentum
- Issue size (smaller issues are more susceptible to subscription-driven pops)
For 1-year post-listing returns (what actually creates wealth):
- Revenue growth rate (40%+ revenue CAGR over 3 years prior)
- Path to profitability (or demonstrated profitability)
- Issue price relative to sector PE
- Promoter credibility and track record
- Market conditions at time of listing
GMP is absent from both lists.
The Subscription Trap
High retail subscription (60x+, 80x+ in the HNI/NII category) is another metric many investors use. But this is driven by leveraged applications - HNIs borrow 4-5x capital to apply for IPOs, planning to sell on listing day. High HNI subscription indicates expected listing day pop from these very investors, creating a self-fulfilling prophecy on listing day but pressure for the following weeks as leveraged positions unwind.
SME IPOs frequently show 100-300x subscriptions. Many then lose 20-40% in the 3 months post-listing as the leverage cycle reverses.
The Right IPO Framework
Stop:
- Checking GMP on Telegram/IPO watch websites
- Treating high subscription numbers as validation
Start:
- Reading the DRHP (15 minutes, as covered in the prior post)
- Checking QIB subscription as a signal of institutional interest
- Comparing issue price to listed peer valuations
- Having a 12-month minimum holding horizon if the business fundamentals are good
Treating IPOs as lottery tickets for listing day gains using GMP as the ticket number is a documented way to lose money with slight worse-than-random accuracy.
Bottom Line
The grey market premium has directional accuracy of roughly 58% - slightly better than a coin flip, dramatically worse than what the financial content machine implies. It measures informal trader sentiment, not company value. The QIB subscription level is a meaningfully more reliable signal of likely listing performance. For long-term wealth creation, neither GMP nor listing day gains matter; the only relevant factors are the fundamentals revealed in the DRHP and your entry price relative to the company’s actual earnings power.
Comments